Psychiatr. pro Praxi, 2007; 4: 158-161

Klinická vodítka NICE léčby depresivních poruch u dětí a adolescentů

prof. MUDr. Ivana Drtílková CSc
Psychiatrická klinika LF MU a FN Brno

Antidepresant medication should not be offered to a child or young person with moderate or severe depression except in combination with a concurrent psychological therapy. Accordance with NICE Guideline, when an antidepressant is prescribed to a child or young people with moderate to severe depression it should be fluoxetine as this is only antidepressant for which clinical trial evidence show that the benefits outweigh the risk. If treatment with fluoxetine is unsuccesful or is not tolerated, consideration should be given to the use of anorther antidepressant – sertraline or citaloprame are the recommended as second-line treatments.

Keywords: depression, children, fluoxetine, sertralin, citalopram, NICE guideline

Published: July 20, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drtílková I. Klinická vodítka NICE léčby depresivních poruch u dětí a adolescentů. Psychiatr. praxi. 2007;8(4):158-161.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Drtílková I. Současný pohled na suicidální riziko v průběhu antidepresivní léčby u dětí. Česká a Slov. Psychiatrie 2007; 1 (103): 22-27.
    2. Emslie G, Wagner K, Kutcher S. et al. Paroxetine treatment in children and adolescents with MDD: a randomised multicenter double-blind, placebo-control trial. J. Am. Acad. Child. Adolesc. Psychiatry 2006; 45 (6): 709-719. Go to original source... Go to PubMed...
    3. Emslie GJ, Rish AJ, Weiberg WA et al. A double-blind randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch gen Psychiatry 1997; 54: 1031-1037. Go to original source... Go to PubMed...
    4. Emslie GJ, Heilingeistein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo controlled, randomized clinical trial. J Am Acad Adolsc Psychiatry 2002; 41: 1205-1215. Go to original source... Go to PubMed...
    5. FDA schedules review for antidepressant/suicidality issue. Child and Adolescent Psychopharmacology 2004; (6), 9: 6-8.
    6. FDA Public Health Advisory, 2004b. Suicidality in children and adolescents being treated with antidepressant medication. Availaible at: htpp//www:fda.gov/cder/drug/antidepressants/SSRIPHA200410htm. Accessed Oct 15, 2004.
    7. Hughes CW, Emslie GJ, Crismon ML et al. The Texas children's medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1999; 38: 1442-1454. Go to original source... Go to PubMed...
    8. Keller MB, Ryan ND, Strober M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J, Am Acad Child Adolesc Psychiatry 2001; 40: 762-772. Go to original source... Go to PubMed...
    9. Kratochvil CH, Vitiello B, Brent D et al. Selecting an antidepressants for the treatment of pediatric depression. J. Am. Acad. Child Adoles. Psychiatry 2006; 45 (3): 371-373. Go to original source... Go to PubMed...
    10. Milin R, Simeon J, Spenst W. Double-blind study of paroxetine in adolescents with unipolar major depression. Abstr. Am. Acad Child Adolesc Psychiatry and Can Acad Child Psychiatry Joint Annual Meeting, Chicago 1999.
    11. Marshall R, Poster K. Risk perception research and the black box warning for SSRIs in children. J. Am. Acad. Child. Adolesc. Psychiatry 2006; 45 (7) 765. Go to original source... Go to PubMed...
    12. National Institute for Health and Clinical Excelence (NICE). Depression in children and young people. Clinical guidelines 28, September 2005. Dostupné: www.nice.org.uk/pdf/CGO28NICE guideline.pdf.
    13. SÚKL. Přehodnocení rizik antidepresiv ze skupiny SSRI a SNRI. Farmakoterap Inf 2005a; (1): 3.
    14. TADS study update: Fluoxetin plus CBT offers most favorable risk/benefit trade off for adolescents with MDD. Child and adolescent psychopharmacology 2004; 6 (9): 1-4.
    15. Taylor D, Paton C, Kerwin R. Prescribing guidelines 2003, 7th edition, MD Martn Dunitz: 169-172.
    16. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preaccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-210. Go to original source... Go to PubMed...
    17. Treatment for Adolescents with Depression Study Team (TADS): Fluoxetine, cognitive-behavioral therapy and thein combination for adolescents with depression. Jama 2004; 292: 807-820. Go to original source... Go to PubMed...
    18. Thase ME Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine nonresponders. J Clin psychiatry 2001; 62: 683-687. Go to original source... Go to PubMed...
    19. Wagner KD, Ambrosini P, Rynn M et al. Sertraline pediatric depression study group. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Jama 2003; 290: 1033-1041. Go to original source... Go to PubMed...
    20. Wagner KD, Robb AS, Findling RL. et al. A randomized placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004b; 161: 107-1083. Go to original source... Go to PubMed...
    21. Whittington C, Kendall T, Fongay P. SSRI in chilhood depression: systematic review of published versus unpublished data. The Lancet 2004; 363 (4): 1341-1345. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.